Transient protein states in designing inhibitors of the MDM2-p53 interaction

Structure

Volumn 21, Issue 12, 2013, Pages 2143-2151

  Bista, Michal ^a   Wolf, Siglinde ^a   Khoury, Kareem ^b   Kowalska, Kaja ^a   Huang, Yijun ^b   Wrona, Ewa ^e   Arciniega, Marcelino ^a   Popowicz, Grzegorz M ^a,d   Holak, Tad A ^a,e   Dömling, Alexander ^b,c  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

INDOLE DERIVATIVE; PROTEIN INHIBITOR; PROTEIN MDM2; PROTEIN P53;

ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG DESIGN; HUMAN; HYDROPHOBICITY; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR DYNAMICS; MOLECULAR MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTON NUCLEAR MAGNETIC RESONANCE; SURFACE PROPERTY; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; HUMANS; HYDROXAMIC ACIDS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR STRUCTURE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTO-ONCOGENE PROTEINS C-MDM2; TRYPTOPHAN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84889562984     PISSN: 09692126     EISSN: 18784186     Source Type: Journal    
DOI: 10.1016/j.str.2013.09.006     Document Type: Article

References (57)

1. J.G. Allen, M.P. Bourbeau, G.E. Wohlhieter, M.D. Bartberger, K. Michelsen, R. Hungate, R.C. Gadwood, R.D. Gaston, B. Evans, and L.W. Mann Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction J. Med. Chem. 52 2009 7044 7053
2. S. Baek, P.S. Kutchukian, G.L. Verdine, R. Huber, T.A. Holak, K.W. Lee, and G.M. Popowicz Structure of the stapled p53 peptide bound to Mdm2 J. Am. Chem. Soc. 134 2012 103 106
3. S. Bailey Collaborative Computational Project, Number 4 The CCP4 suite: programs for protein crystallography Acta Crystallogr. D Biol. Crystallogr. 50 1994 760 763
4. M. Bista, K. Kowalska, W. Janczyk, A. Dömling, and T.A. Holak Robust NMR screening for lead compounds using tryptophan-containing proteins J. Am. Chem. Soc. 131 2009 7500 7501
5. C.J. Brown, S. Lain, C.S. Verma, A.R. Fersht, and D.P. Lane Awakening guardian angels: drugging the p53 pathway Nat. Rev. Cancer 9 2009 862 873
6. Y.S. Chang, B. Graves, V. Guerlavais, C. Tovar, K. Packman, K.H. To, K.A. Olson, K. Kesavan, P. Gangurde, and A. Mukherjee Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy Proc. Natl. Acad. Sci. USA 110 2013 E3445 E3454
7. H.F. Chen, and R. Luo Binding induced folding in p53-MDM2 complex J. Am. Chem. Soc. 129 2007 2930 2937
8. C.F. Cheok, C.S. Verma, J. Baselga, and D.P. Lane Translating p53 into the clinic Nat. Rev. Clin. Oncol. 8 2011 25 37
9. A. Czarna, G.M. Popowicz, A. Pecak, S. Wolf, G. Dubin, and T.A. Holak High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx Cell Cycle 8 2009 1176 1184
10. A. Czarna, B. Beck, S. Srivastava, G.M. Popowicz, S. Wolf, Y.J. Huang, M. Bista, T.A. Holak, and A. Dömling Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists Angew. Chem. Int. Ed. Engl. 49 2010 5352 5356
11. T. Darden, D. York, and L. Pedersen Particle mesh Ewald: an N×log(N) method for Ewald sums in large systems J. Chem. Phys. 98 1993 10089 10092
12. S.G. Dastidar, D.P. Lane, and C.S. Verma Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2 J. Am. Chem. Soc. 130 2008 13514 13515
13. S.G. Dastidar, D.P. Lane, and C.S. Verma Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100 BMC Bioinformatics 10 Suppl 15 2009 S6
14. Q.J. Ding, Z.M. Zhang, J.J. Liu, N. Jiang, J. Zhang, T.M. Ross, X.J. Chu, D. Bartkovitz, F. Podlaski, and C. Janson Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development J. Med. Chem. 56 2013 5979 5983
15. A. Dömling Recent developments in isocyanide based multicomponent reactions in applied chemistry Chem. Rev. 106 2006 17 89
16. A. Dömling Small molecular weight protein-protein interaction antagonists: an insurmountable challenge? Curr. Opin. Chem. Biol. 12 2008 281 291
17. A. Dömling, W. Wang, and K. Wang Chemistry and biology of multicomponent reactions Chem. Rev. 112 2012 3083 3135
18. L. D'Silva, P. Ozdowy, M. Krajewski, U. Rothweiler, M. Singh, and T.A. Holak Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy J. Am. Chem. Soc. 127 2005 13220 13226
19. L.M. Espinoza-Fonseca, and J.G. Trujillo-Ferrara Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations Biopolymers 83 2006 365 373
20. L.M. Espinoza-Fonseca, and J. García-Machorro Aromatic-aromatic interactions in the formation of the MDM2-p53 complex Biochem. Biophys. Res. Commun. 370 2008 547 551
21. B. Graves, T. Thompson, M. Xia, C. Janson, C. Lukacs, D. Deo, P. Di Lello, D. Fry, C. Garvie, and K.S. Huang Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization Proc. Natl. Acad. Sci. USA 109 2012 11788 11793
22. B. Hess, H. Bekker, H.J.C. Berendsen, and J.G.E.M. Fraaije LINCS: a linear constraint solver for molecular simulations J. Comput. Chem. 18 1997 1463 1472
23. W.G. Hoover Canonical dynamics: equilibrium phase-space distributions Phys. Rev. A 31 1985 1695 1697
24. B. Hu, D.M. Gilkes, and J. Chen Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX Cancer Res. 67 2007 8810 8817
25. Y. Huang, S. Wolf, D. Koes, G.M. Popowicz, C.J. Camacho, T.A. Holak, and A. Dömling Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists ChemMedChem 7 2012 49 52
26. A.C. Joerger, and A.R. Fersht Structural biology of the tumor suppressor p53 Annu. Rev. Biochem. 77 2008 557 582
27. W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, and M.L. Klein Comparison of simple potential functions for simulating liquid water J. Chem. Phys. 79 1983 926 935
28. W. Kabsch Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants J. Appl. Cryst. 26 1993 795 800
29. G.A. Kaminski, R.A. Friesner, J. Tirado-Rives, and W.L. Jorgensen Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides J. Phys. Chem. B 105 2001 6474 6487
30. D. Koes, K. Khoury, Y. Huang, W. Wang, M. Bista, G.M. Popowicz, S. Wolf, T.A. Holak, A. Dömling, and C.J. Camacho Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists PLoS ONE 7 2012 e32839
31. M. Krajewski, U. Rothweiler, L. D'Silva, S. Majumdar, C. Klein, and T.A. Holak An NMR-based antagonist induced dissociation assay for targeting the ligand-protein and protein-protein interactions in competition binding experiments J. Med. Chem. 50 2007 4382 4387
32. P.H. Kussie, S. Gorina, V. Marechal, B. Elenbaas, J. Moreau, A.J. Levine, and N.P. Pavletich Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain Science 274 1996 948 953
33. H. Lee, K.H. Mok, R. Muhandiram, K.H. Park, J.E. Suk, D.H. Kim, J. Chang, Y.C. Sung, K.Y. Choi, and K.H. Han Local structural elements in the mostly unstructured transcriptional activation domain of human p53 J. Biol. Chem. 275 2000 29426 29432
34. A. Macchiarulo, N. Giacchè, A. Carotti, M. Baroni, G. Cruciani, and R. Pellicciari Targeting the conformational transitions of MDM2 and MDMX: insights into dissimilarities and similarities of p53 recognition J. Chem. Inf. Model. 48 2008 1999 2009
35. M.A. McCoy, J.J. Gesell, M.M. Senior, and D.F. Wyss Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation Proc. Natl. Acad. Sci. USA 100 2003 1645 1648
36. S. Mori, C. Abeygunawardana, M.O. Johnson, and P.C. van Zijl Improved sensitivity of HSQC spectra of exchanging protons at short interscan delays using a new fast HSQC (FHSQC) detection scheme that avoids water saturation J. Magn. Reson. B. 108 1995 94 98
37. G.N. Murshudov, A.A. Vagin, and E.J. Dodson Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr. D Biol. Crystallogr. 53 1997 240 255
38. S. Nose A unified formulation of the constant temperature molecular dynamics methods J. Chem. Phys. 81 1984 511 519
39. M. Parrinello, and A. Rahman Polymorphic transitions in single crystals: a new molecular dynamics method J. Appl. Physiol. 52 1981 7182 7190
40. A. Perrakis, R. Morris, and V.S. Lamzin Automated protein model building combined with iterative structure refinement Nat. Struct. Biol. 6 1999 458 463
41. G.M. Popowicz, A. Czarna, U. Rothweiler, A. Szwagierczak, M. Krajewski, L. Weber, and T.A. Holak Molecular basis for the inhibition of p53 by Mdmx Cell Cycle 6 2007 2386 2392
42. G.M. Popowicz, A. Czarna, and T.A. Holak Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain Cell Cycle 7 2008 2441 2443
43. G.M. Popowicz, A. Czarna, S. Wolf, K. Wang, W. Wang, A. Dömling, and T.A. Holak Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery Cell Cycle 9 2010 1104 1111
44. G.M. Popowicz, A. Dömling, and T.A. Holak The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious Angew. Chem. Int. Ed. Engl. 50 2011 2680 2688
45. S. Shangary, and S. Wang Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy Annu. Rev. Pharmacol. Toxicol. 49 2009 223 241
46. S.A. Showalter, L. Bruschweiler-Li, E. Johnson, F. Zhang, and R. Bruschweiler Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft J. Am. Chem. Soc. 130 2008 6472 6478
47. R. Stoll, C. Renner, S. Hansen, S. Palme, C. Klein, A. Belling, W. Zeslawski, M. Kamionka, T. Rehm, and P. Mühlhahn Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53 Biochemistry 40 2001 336 344
48. M. Uesugi, and G.L. Verdine The α-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2 Proc. Natl. Acad. Sci. USA 96 1999 14801 14806
49. S. Uhrinova, D. Uhrin, H. Powers, K. Watt, D. Zheleva, P. Fischer, C. McInnes, and P.N. Barlow Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding J. Mol. Biol. 350 2005 587 598
50. A. Vagin, and A. Teplyakov MOLREP: an automated program for molecular replacement J. Appl. Cryst. 30 1997 1022 1025
51. D. Van Der Spoel, E. Lindahl, B. Hess, G. Groenhof, A.E. Mark, and H.J. Berendsen GROMACS: fast, flexible, and free J. Comput. Chem. 26 2005 1701 1718
52. S.M. Vogel, M.R. Bauer, A.C. Joerger, R. Wilcken, T. Brandt, D.B. Veprintsev, T.J. Rutherford, A.R. Fersht, and F.M. Boeckler Lithocholic acid is an endogenous inhibitor of MDM4 and MDM2 Proc. Natl. Acad. Sci. USA 109 2012 16906 16910
53. M. Wade, Y.C. Li, and G.M. Wahl MDM2, MDMX and p53 in oncogenesis and cancer therapy Nat. Rev. Cancer 13 2013 83 96
54. Z.X. Wang An exact mathematical expression for describing competitive binding of two different ligands to a protein molecule FEBS Lett. 360 1995 111 114
55. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, and C. Klein In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
56. C. Zhan, K. Varney, W. Yuan, L. Zhao, and W. Lu Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: the functional role of Ser17 phosphorylation in MDM2 reexamined J. Am. Chem. Soc. 134 2012 6855 6864
57. Y. Zhao, L. Liu, W. Sun, J. Lu, D. McEachern, X. Li, S. Yu, D. Bernard, P. Ochsenbein, and V. Ferey Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors J. Am. Chem. Soc. 135 2013 7223 7234